EPB41L4A

Across TCGA pan-cancer cohorts, EPB41L4A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EPB41L4A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EPB41L4A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB41L4A expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, KIRP, and CHOL are the cancer types where EPB41L4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.971	0.615	.003	36	view →
KIRP	DFS	Median	II,III,IV	0.038	0.783	<.001	15	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
STAD	DFS	Median	III,IV	0.882	0.464	.037	3	view →
COAD	OS	Median	All	0.405	0.679	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EPB41L4A–UCEC (DFS)

Open the UCEC breakdown →